The role of rituximab in the treatment of primary central nervous system lymphoma

Ruben Van Dijck, Jeanette K. Doorduijn, Jacoline E.C. Bromberg*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)

Abstract

Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.

Original languageEnglish
Article number1920
JournalCancers
Volume13
Issue number8
DOIs
Publication statusPublished - 16 Apr 2021

Fingerprint

Dive into the research topics of 'The role of rituximab in the treatment of primary central nervous system lymphoma'. Together they form a unique fingerprint.

Cite this